Verastem/VSTM

$12.70

5.48%
-
1D1W1MYTD1YMAX

About Verastem

Verastem, Inc. is a late-stage development biopharmaceutical company. The Company’s pipeline is focused on anticancer agents that inhibit critical signaling pathways in cancer that promote cancer cell survival and tumor growth, particularly rapidly accelerated fibrosarcoma (RAF)/mitogen-activated protein kinase kinase (MEK) inhibition and focal adhesion kinase (FAK) inhibition. The Company’s advanced product candidates, Avutometinib (VS-6766) and Defactinib, are being investigated in both preclinical and clinical studies for the treatment of various solid tumors, including, but not limited to low-grade serous ovarian cancer (LGSOC), non-small cell lung cancer (NSCLC), colorectal cancer (CRC), pancreatic cancer, and melanoma. VS-6766 is an orally available small molecule RAF/MEK clamp. Defactinib is an oral small molecule inhibitor of FAK and proline-rich tyrosine kinase (PYK2) that is being evaluated as a potential combination therapy for various solid tumors.
Ticker
VSTM
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Daniel Paterson
Employees
57
Headquarters
Cambridge, United States

Verastem Metrics

BasicAdvanced
$320.9M
Market cap
-
P/E ratio
-$4.04
EPS
0.49
Beta
-
Dividend rate

What the Analysts think about Verastem

Analyst Ratings

Majority rating from 8 analysts.
Buy

Price Targets

Average projection from 7 analysts.
126.69% upside
High $36.00
Low $17.50
$12.70
Current price
$28.79
Average price target

Verastem Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-20M
-17.36%
Profit margin
0%
-

Verastem Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 11.02%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.96
-$0.96
-$1.37
-$0.75
-
Expected
-$1.18
-$0.98
-$1.06
-$0.84
-$0.62
Surprise
-18.37%
-2.44%
29.25%
-11.02%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Verastem stock

Buy or sell Verastem stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing